ReviewFrontiers in immunology2021
TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Conserved Pathways, Divergent Outcomes: A Cross-Species Genomic Perspective on the Cancer-Neurodegeneration Paradox.International journal of molecular sciences · 2026Review
- Immune Landscape and Application of Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2025Review
- TREM2-mediated regulation of myeloid cells in the tumor microenvironment: new insights and therapeutic prospects.NPJ precision oncology · 2025Review
- Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumab.Research square · 2025Article
- Defining gastric cancer ecology: the crucial roles of TREM2Communications biology · 2025Article
- Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.Journal of hematology & oncology · 2025Review
- Targeting myeloid cells to improve cancer immune therapy.Frontiers in immunology · 2025Review
- Therapeutic targeting of tumour-associated macrophage receptors.Immunotherapy advances · 2025Review
- TREM2 signaling pathway in sepsis-induced acute lung injury: physiology, pathology, and therapeutic applications.Frontiers in medicine · 2025Review
- Potential of natural products and gut microbiome in tumor immunotherapy.Chinese medicine · 2024Review
- HMGB1/TREM2 positive feedback loop drives the development of radioresistance and immune escape of glioblastoma by regulating TLR4/Akt signaling.Journal of translational medicine · 2024Article
- Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.Neuro-oncology · 2024Article
- Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression.Frontiers in oncology · 2024Review
- Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.Human vaccines & immunotherapeutics · 2023Review
- Role of neuroinflammation in neurodegeneration development.Signal transduction and targeted therapy · 2023Review
- The Wheel of p53 Helps to Drive the Immune System.International journal of molecular sciences · 2023Review
- The immunoregulatory effect of the TREM2-agonist Sulfavant A in human allogeneic mixed lymphocyte reaction.Frontiers in immunology · 2023Article
- TREM2 as an independent predictor of poor prognosis promotes the migration via the PI3K/AKT axis in prostate cancer.American journal of translational research · 2023Article
- Digits in a dish: AnFrontiers in cell and developmental biology · 2023Article
- The Chromatin-Oxygen Sensor GeneInternational journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, immune checkpoint inhibitors have been successively approved and widely used in clinical cancer treatments, however, the overall response rates are very low and almost all cancer patients eventually progressed to drug resistance, this is mainly due to the intricate tumor microenvironment and immune escape mechanisms of cancer cells. One of the main key mechanisms leading to the evasion of immune attack is the presence of the immunosuppressive microenvironment within tumors. Recently, several studies illustrated that triggering receptor expressed on myeloid cells-2 (TREM2), a transmembrane receptor of the immunoglobulin superfamily, was a crucial pathology-induced immune signaling hub, and it played a vital negative role in antitumor immunity, such as inhibiting the proliferation of T cells. Here, we reviewed the recent advances in the study of TREM2, especially focused on its regulation of tumor-related immune signaling pathways and its role as a novel target in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.